spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  cholestatic liver disease 

 HSMN NewsFeed - 21 Mar 2019
Mirum Pharmaceuticals Appoints Chris Peetz as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Jun 2018
Albireo Appoints Jason G. Duncan as General Counsel and Secretary
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Jun 2018
Albireo Elects Anne Klibanski and Stephanie Okey to Board of Directors
Biopharmaceuticals Gastroenterology Personnel
 HSMN NewsFeed - 14 Oct 2016
Intercept Pharmaceuticals Receives Positive CHMP Opinion for Ocaliva(R) (Obeticholic Acid) for the Treatment of Primary Biliary Cholangitis in the European Union
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 11 Nov 2015
Amplyx Pharmaceuticals Secures $40.5 Million in Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 11 Mar 2014
Lumena Pharmaceuticals Raises $45 Million in Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 26 Sep 2013
Lumena Pharmaceuticals Receives Orphan Drug Designation from US Food & Drug Administration for LUM001 in Four Rare Liver Diseases
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 Nov 2012
Albireo Has Been Granted Orphan Drug Designation for A4250 from the US FDA for the Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC) and for Primary Biliary Cirrhosis (PBC)
Biopharmaceuticals
 HSMN NewsFeed - 1 Oct 2007
Axcan Licenses Rights to Cx401, an Innovative Biological Product in Development for the Treatment of Perianal Fistulas, a Significant Unmet Medical Need
Biopharmaceuticals Regenerative Medicine
 HSMN NewsFeed - 2 Aug 2007
Axcan Pharma Submits Complete New Drug Application for ULTRASE
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 14 Jun 2007
Axcan Pharma Initiates MAX-002 Phase III Clinical Trial to Evaluate the Efficacy and Safety of a High-Concentration 1 Gram Mesalamine Suppository
Biopharmaceuticals
 HSMN NewsFeed - 7 May 2007
Axcan Announces the U.S. Launch of PYLERA, an Innovative 3-in-1 Capsule Triple Therapy for the Eradication of Helicobacter Pylori
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 29 Sep 2006
Axcan Receives FDA Approval Letter for PYLERA'TM' -Formerly Known as HELIZIDE-, an Innovative 3-in-1 Capsule Triple Therapy for the Eradication of Helicobacter Pylori
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 26 Sep 2006
Axcan and AGI Therapeutics Sign Exclusive License and Co-Development Agreement for the Next-Generation Therapy for GERD and the Control of Nocturnal Acid Breakthrough
Biopharmaceuticals Gastroenterology Licensing
 HSMN NewsFeed - 10 May 2006
Axcan Pharma appoints new Senior Vice President and Chief Scientific Officer
Biopharmaceuticals Personnel
Return to NewsFeed  

 Additional items found! 28

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 28 additional stories matching:
cholestatic liver disease
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!